Psychiatr. praxi. 2015;16(2):51-55

Drug interactions in psychiatry in theory and in practice

MUDr.Michal Prokeš, PharmDr.Josef Suchopár
Infopharm, a. s., Praha

Drug interactions are one of the common drug-related problems in modern medicine. In this review the mechanisms of drug-drug

interactions (DDI) of antipsychotics and antidepresants are presented as well as common guidenance for general approach to DDIs

in medical praxis. Many of the DDIs in psychiatric praxis are generated by pharmacokinetic action between interacting drugs, where

their plasma concentrations are changed by inhibition or induction of cytochrom P 450 isoenzymes, mainly by CYP2D6 or CYP3A4, and

of P-glycoprotein. Prescribing physicians should consider risks and benefits of combined drug therapy in individual patients and take

measures to minimize the adverse drug reactions.

Keywords: drug-drug interactions, antipsychotic drugs, antidepresives, QT interval prolongation, serotonine syndrome

Published: May 18, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Prokeš M, Suchopár J. Drug interactions in psychiatry in theory and in practice. Psychiatr. praxi. 2015;16(2):51-55.
Download citation

References

  1. Pirmohamed M, et al. Averse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 326: 15-19, http://www.bmj.com/cgi/reprint/329/7456/15. Go to original source... Go to PubMed...
  2. Wienkers LC, Heath TG. Predicting in vivo drug interactions from in vitro drug discovery data. Nad Rev Drug Discov 2005; 4: 825-833 Go to original source... Go to PubMed...
  3. el-Yazigi A, Chaleby K, Gad A, Raines DA. Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. J Clin Pharmacol 1995; 35: 17-21. Go to original source... Go to PubMed...
  4. Preskorn SH, Baker B: Fatality associated with combined fluoxetine-amitriptyline therapy. JAMA 1997; 277: 1682. Go to original source... Go to PubMed...
  5. Albers LJ, Reist C, Helmeste D, et al: Paroxetine shifts imipramine metabolism. Psychiatry Res 1996; 95: 186-196. Go to original source... Go to PubMed...
  6. Leucht S, Hackl HJ, Steimer W, et al: Effect of adjunctive paroxetine on serum levels and side-effects of tricyclic antidepressants in depressive inpatients.
  7. Buzková H, Pechandová K, Slanař O and Perlík F: Frequency of single nucleotide polymofphism of CYP2D6 in the Czech population. Cell Biochem Funct 2008; 26: 76-78. Go to original source... Go to PubMed...
  8. van der Weidke K, vander Weidke J: The influence of the CYP3A4*22 polymorphism and CYP2D6 polymorphism on serum concentrations of aripiprazole, haloperidol, pomozide, and risperidone in psychiatric patients. J Clin Psychopharmacol 2015 Apr 10 (Epub ahead of print). Go to original source... Go to PubMed...
  9. van der Weidke K, vander Weidke J: The influence of the CYP3A4*22 polymorphism on serum concentrations of quetiapine in psychiatric patients. J Clin Psychopharmacol 2014; 34: 256-260. Go to original source... Go to PubMed...
  10. Akamine Y, Yasuri-Furukori N, Ieiri I, Uno T. Psychotropic drug-drug interactions involving P-glycoprotein. CNS Drugs 2012; 26: 959-973. Go to original source... Go to PubMed...
  11. Moons T, de Roo M, Claes S, Dom G. Relationship between P-glycoprotein and second-generation antipsychotics. Pharmacogenomics 2011; 12: 1193-1211. Go to original source... Go to PubMed...
  12. Sandson NB, Armstrong SC, Cozza KL. An overview od psychotropic drug-drug interactions. Psychosomatics 2005; 46: 464-494. Go to original source... Go to PubMed...
  13. Prokeš M, Suchopár J. Spolehlivost počítačových programů poskytujících elektronickou podporou preskripce v oblasti lékových interakcí. Klin Farmakol Farm 2010; 24(4): 190-196, http://www.klinickafarmakologie.cz/pdfs/far/2010/04/07.pdf.
  14. http://www.sukl.cz/modules/medication/search.php.




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.